Since 2015 there have been a few pharmaceutical companies working on a new cholesterol-lowering drug type as a replacement for the older class of statin drugs, such as Lipitor. Lipitor was the best-selling drug of all time, but its patent expired a few years ago. The new mantra is getting LDL cholesterol levels lower than statin drugs. The drug class of these new cholesterol-lowering drugs is a PCSK9 inhibitor. Of course, this is madness for two reasons: (1) Cholesterol and fats, in general, are not the cause of heart disease; (2) cholesterol is vital for hormone production and nervous system and brain function. The fact is that cholesterol is vitally essential for good health, and lowering cholesterol artificially can and does lead to more immediate health problems, and a lower life expectancy. So why the focus for a new cholesterol-lowering drug? Once again, we follow the money.
A 2015 study in Critical Care Medicine is titled, “Lipid Paradox in Acute Myocardial Infarction- The Association with 30-Day In-Hospital Mortality.” This study followed 724 hospitalized patients who suffered an acute heart attack (i.e., myocardial infarction). The scientists attempted to clarify the relationship between the lipid profiles and the 30-day mortality in patients who suffered a heart attack. The authors found that those with lower LDL-cholesterol and triglyceride levels had a significantly elevated mortality risk when compared to patients with higher LDL-cholesterol and triglyceride levels. Why would lowered cholesterol and triglyceride levels be associated with a higher mortality rate? Fats from triglycerides are a major energy source and LDL-cholesterol is critical for cell membrane synthesis and is needed to fight infections. Adequate LDL-cholesterol and triglyceride levels may be critical for cell function and survival in the case of a heart attack—as well as in other conditions. Folks, we have been hoodwinked to believe that we must all take cholesterol-lowering medications in order to prevent and/or treat heart disease. People do not get heart disease because their cholesterol level is elevated. Remember, 50% of patients who suffer a heart attack have normal cholesterol levels.
Shocking news! Two studies were recently published that endorse 2013 guidelines for a wider use of statin drugs. As reported in the Journal of the American Medical Association (JAMA), out of over 2400 people, 39% were statin eligible, compared with 14% by the old 2004 guidelines. In one fell swoop, the amount of people recommended for statin use was tripled! This is not surprising given the amount of revenue from statin drug sales. Who makes the guidelines? Doctors on Big Pharma payroll, that’s who.